Pharma Factual

Strict data privacy laws like the GDPR have significantly reduced biopharmaceutical R&D investment—especially among smaller firms—highlighting the need for U.S. policymakers to reform HIPAA, pass innovation-friendly federal privacy legislation, and invest in privacy-enhancing technologies to protect both privacy and progress in medical research.

The White House’s AI Action Plan highlights how upgrading labs, data infrastructure, and research models is essential to unlock AI’s full potential in accelerating drug discovery and keeping the United States at the forefront of biopharmaceutical innovation.

A cornerstone of U.S. biopharmaceutical leadership, PDUFA has dramatically accelerated drug approvals and patient access, but looming FDA budget cuts threaten to unravel three decades of progress.

Microgravity could be the next big breakthrough in drug development, but only if policymakers act now to turn space-based research from potential into progress.

To stay ahead in biopharma and ensure new therapies work for everyone, the U.S. must fix the diversity gap in biomedical research.

Cutting federal life sciences funding threatens U.S. biopharmaceutical innovation, while China is ramping up investment to dominate the industry.

The FDA’s Breakthrough Therapy Designation program underscores the benefits of targeted regulatory innovation. Its success offers valuable lessons for policymakers navigating the balance between speed and safety in approving life-saving therapies.